

68 uncommon and sparsely reported in the literature, high-
69 lighting the need to maintain a high index of suspicion
70 even in atypical populations.

71 Furthermore, KFD may precede, coexist with, or repre-
72 sent the initial clinical manifestation of SLE, as observed
73 in this patient. Early recognition of this association is
74 essential, since KFD is typically a self-limited condition,
75 whereas SLE requires timely immunosuppressive treat-
76 ment to prevent organ damage and long-term complica-
77 tions. In this context, excisional lymph node biopsy was
78 crucial to establish the correct diagnosis and to exclude
79 malignant or infectious processes.

80 Finally, the limited number of reported cases of KFD
81 associated with SLE in Latin America and Mexico con-
82 fers additional value to this report, as it contributes to
83 expanding regional knowledge of this entity, raises aware-
84 ness among clinicians regarding its early recognition, and
85 reinforces the importance of including it in the differen-
86 tial diagnosis of young patients presenting with fever of
87 unknown origin and lymphadenopathy.

88 Case Description

89 An 18-year-old male with no relevant allergic history pre-
90 sented to the emergency department. He reported a family
91 history of rheumatoid arthritis and vitiligo on his maternal
92 side. He denied exposure to relevant zoonoses. His per-
93 sonal history included multiple hospitalizations during
94 childhood for febrile seizures (Referred to as generalized
95 tonic-clonic seizures lasting 4 minutes, without available
96 imaging studies), currently without treatment, with the
97 last episode documented 7 years prior.

98 He arrived with a 1-month history of persistent
99 evening-predominant fever reaching temperatures up to
100 39°C, with mild response to antipyretics, accompanied
101 by malaise, asthenia, adynamia, myalgias, arthralgias,
102 a non-pruritic rash on the trunk and upper extremities
103 (Figure 1), and generalized lymphadenopathy, which is
104 painful, firm, unilateral, and approximately 2 cm on pal-
105 pation, predominantly in the cervical region associated
106 with pharyngitis. He also reported unintentional weight
107 loss and night sweats. On admission, vital signs showed
108 tachycardia (125 bpm) and fever (38.8°C).

109 Initial laboratory studies revealed significant pan-
110 cytopenia: normocytic normochromic anemia (Hb 8 g/
111 dl; MCV 86 fl; MCH 30 pg) with features of an anemic
112 syndrome; leukopenia of 1,500 cells/mm³ with absolute
113 neutropenia of 480 cells/mm³; and thrombocytopenia of
114 115,000 platelets/mm³. Renal function was preserved
115 (urea 30 mg/dl, creatinine 0.7 mg/dl). Liver function
116 tests were normal. The direct Coombs test was negative.
117 Peripheral blood smear showed no abnormalities. Iron
118 studies revealed no deficiency (Serum iron: 100 mg/dl,
119 transferrin saturation of 30%, total iron binding capacity
120 of 321 mg/dl). Serologies for Human immunodeficiency
121 virus, Hepatitis B virus, Hepatitis C virus dengue, Rose
122 Bengal test, sepsis panel, throat culture, procalcitonin,

CUTANEOUS MANIFESTATIONS



Figure 1. Erythematous plaque on the right cheek region, with a slightly raised surface and no visible desquamative changes.

heterophile antibodies, cytomegalovirus, and cultures—
all negative. Acute-phase reactants were elevated: ESR 58
mm/h, CRP 384 mg/l, and ferritin 753 ng/ml.

Chest, abdominal, and pelvic computed tomography
(CT) imaging demonstrated multiple axillary, mesenteric,
retroperitoneal, pelvic, and inguinal lymph nodes, as well
as hepatosplenomegaly (Figure 2). Based on these find-
ings, a diagnosis of fever of unknown origin was estab-
lished, and the corresponding workup was initiated.

Given the presence of febrile neutropenia, empiric
antimicrobial therapy was started with trimethoprim-sul-
famethoxazole 160/800 mg every 72 hours, fluconazole
200 mg daily, and acyclovir 400 mg every 12 hours.

A transthoracic echocardiogram was performed due
to the presence of a systolic murmur at the mitral area,
showing no vegetations; a hyperdynamic heart with Left
ventricular ejection fraction of 64% was observed. The
murmur was attributed to the anemic syndrome.

Rheumatologic evaluation showed positive antinuclear
antibodies by immunofluorescence at a titer of 1:1,280
with a homogeneous pattern, normal complement levels,
and negative antiphospholipid antibodies, rheumatoid fac-
tor, and anti-Smith antibodies. Due to significant osteo-
muscular symptoms, CPK, aldolase, and anti-U1-RNP
antibodies were obtained, all of which were negative.

An inguinal lymph node biopsy was performed due
to initial suspicion of hematologic disease (lymphoma)
or tuberculous lymphadenitis (Figure 3). Histopathology
revealed chronic necrotizing lymphadenitis with areas of
immunoblastic atypia. Zones of necrosis were observed

ABDOMINOPELVIC CT SCAN




Figure 2. Lymph node chains. Multiple mesenteric, retroperitoneal, pelvic, and inguinal lymphadenopathies (red arrow), measuring up to 18 mm.

INGUINAL LYMPH NODE BIOPSY




Figure 3. Close-up view of the cut surface of the largest lymph node, showing whitish areas (necrosis^a yellow arrow) and regions of congestion.

153 with dense inflammatory infiltrates, abundant histiocytes
154 exhibiting phagocytosis of cellular debris and erythro-
155 cytes, absence of neutrophils, and no evidence of fungi,
156 parasites, intranuclear inclusions, or overt malignancy
157 (Figures 4 and 5).

158 These findings supported the diagnosis of necrotizing
159 lymphadenitis consistent KFD. Due to its frequent associ-
160 ation with SLE, the immunologic profile was expanded,
161 revealing elevated double-stranded DNA antibodies (800
162 IU/ml).

Clinical reevaluation identified lupus stigmata, and 163
the score on the European Alliance of Associations 164
for Rheumatology (EULAR)/American College of 165
Rheumatology (ACR) classification criteria reached 20 166
points: fever (2 points), alopecia (2 points), thrombo- 167
cytopenia (4 points), positive anti-dsDNA antibodies 168
(6 points) and arthritis (6 points), considering that ≥ 10 169
points is classifying for lupus, the diagnosis of KFD sec- 170
ondary to SLE is established. 171

Following EULAR recommendations for the treat- 172
ment of SLE, corticosteroid treatment was initiated due 173




Figure 4. A granular necrotic area with abundant karyorrhexis is observed, intermingled with a dense infiltrate of histiocytes and small lymphocytes.




Figure 5. Numerous histiocytes with broad, pale cytoplasm—several displaying plasmacytoid morphology—are identified, intimately mixed with small lymphocytes and abundant nuclear debris.

The patient improved and was discharged with scheduled rheumatological follow-up, and was prescribed medical management with prednisone (40 mg/day) for 2 weeks, after which the dose was reduced (5 mg/day). In addition, treatment with hydroxychloroquine plus azathioprine was continued.

Discussion

A male patient in his second decade of life presented with persistent fever refractory to antipyretics and generalized lymphadenopathy. Given the criteria for fever of unknown origin in an immunocompetent patient [2], extensive laboratory and imaging studies were performed, all of which were negative for infectious etiologies. CT confirmed systemic lymphadenopathy, raising suspicion for lymphoma or tuberculous lymphadenitis, prompting a lymph node biopsy. Histopathology established the diagnosis of KFD.

KFD, first described in 1972 and also known as necrotizing histiocytic lymphadenitis [1], typically presents with fever of unknown origin and small-volume lymphadenopathy, generally <1 cm, helping distinguish it from hematologic malignancies [3]. Although most frequently reported in Asian populations [4], cases have also been described in Latin America, with scarce reports in Mexico. It predominantly affects individuals <40 years and is more common in females [5].

Its etiology remains unclear, with a leading hypothesis supporting a viral–autoimmune mechanism. Although multiple infectious and noninfectious triggers have been proposed, none show definitive causality. In contrast, strong associations with autoimmune diseases—particularly SLE, Sjögren syndrome, and autoimmune thyroiditis—have been documented. In this patient, KFD may represent an early manifestation of SLE. Genetic susceptibility has been suggested through shared HLA genotypes (HLA-Cw7, HLA-B25), and periodontal infections have been proposed as possible factors [1].

Clinically, KFD presents heterogeneously. Cervical lymphadenopathy occurs in 55%–99% of cases, although up to half may show generalized involvement. Systemic manifestations include fever, weight loss, arthritis, leukopenia, and cutaneous lesions, reported in up to 40% [6]. This variability underscores its importance in the differential diagnosis of febrile lymphadenopathy in young individuals.

Diagnosis is challenging due to overlap with malignant lymphoma and SLE. Laboratory and imaging findings are nonspecific; thus, excisional lymph node biopsy remains the diagnostic gold standard. Histology reveals necrosis with karyorrhexis, prominent histiocytic infiltrates, and absence of neutrophils, features essential for differentiating KFD from other clinically similar disorders [7].

Comprehensive evaluation is required to rule out infectious, neoplastic, and hematologic causes, including toxoplasmosis, cytomegalovirus, head and neck malignancies,

174 to the severity of the clinical presentation and pancytopenia. Methylprednisolone 1,000 mg/day was administered, 175 along with steroid-sparing therapy using hydroxychloroquine 200 mg/day and azathioprine 50 mg/day. The 176 patient showed significant clinical improvement from the 177 second day of treatment, with progressive normalization 178 of all three hematological cell lines (Hb increased from 179 8 to 10 g/dl; leukopenia from 1,448 to 5,960 cells/mm³; 180 and thrombocytopenia from 62,000 to 152,000 platelets/ 181 mm³). Treatment was initiated with corticosteroids due to 182 the severity of the presentation and pancytopenia, admin- 183 istering prednisone 100 mg/day, along with steroid-spar- 184 ing therapy using hydroxychloroquine 200 mg/day and 185 azathioprine 50 mg/day. The patient showed significant 186 clinical improvement beginning on the second day of 187 treatment, with progressive normalization of all three 188 hematologic cell lines. 189 190

245 Castleman disease, tuberculous lymphadenitis, and hemo-
246 phagocytic lymphohistiocytosis [3].

247 Symptomatic or persistent cases may require systemic
248 therapy with corticosteroids, Nonsteroidal anti-inflamma-
249 tory drugs, antipyretics, or antimalarials. When associated
250 with SLE, treatment must address lupus activity with cor-
251 ticosteroids and hydroxychloroquine, reserving additional
252 immunosuppression for severe or refractory cases [8].

253 Although the coexistence of KFD and autoimmune dis-
254 eases—particularly SLE—has been described, it remains
255 uncommon [9]. Its identification in a male patient is nota-
256 ble given the female predominance in SLE. Using the
257 2019 EULAR/ACR criteria, which have high sensitivity
258 and specificity [10], the patient reached a score of 20, con-
259 firming concomitant KFD and SLE.

260 KFD typically resolves spontaneously within 1–4
261 months, making observation the most common man-
262 agement approach [11]. Although generally benign,
263 recurrences occur in up to 11.3% of cases, and rare com-
264 plications such as cardiac tamponade, pleural effusion,
265 and polyarteritis nodosa have been reported [1].

266 Reviewing similar published cases provides relevant
267 comparisons and strengthens diagnostic suspicion, rein-
268 forcing the need to include KFD in the differential diag-
269 nosis of febrile lymphadenopathy.

270 Conclusion

271 The coexistence of KFD and SLE should be considered
272 in patients with persistent fever, generalized lymphade-
273 nopathy, and pancytopenia. This association represents
274 a diagnostic challenge, particularly in low-prevalence
275 regions and in male patients. Histopathological evaluation
276 is essential to distinguish KFD from hematologic, infec-
277 tious, or autoimmune conditions with similar features.
278 Early recognition is crucial, as KFD is typically self-lim-
279 ited, whereas SLE requires timely immunosuppressive
280 therapy to prevent complications. A comprehensive and
281 prompt diagnostic approach can significantly influence
282 patient outcomes.

283 What is new?

- 284 ● The association between KFD and SLE may occur even
285 in male patients, despite the higher prevalence of SLE
286 in females; thus, the diagnosis should not be excluded
287 based on sex.
- 288 ● Histopathological examination is essential to differentiate
289 KFD from other causes, such as lymphoma, tuberculosis, or
290 lupus lymphadenitis, enabling accurate and timely diagnosis.
- 291 ● Early recognition of the KFD–SLE association is critical,
292 since KFD is typically self-limited, whereas SLE requires
293 urgent immunosuppressive therapy to prevent complica-
294 tions and improve prognosis.

295 List of Abbreviations

296 ACR	American College of Rheumatology
297 ANA	Antinuclear antibodies

anti-dsDNA	Anti–double-stranded DNA antibodies	298
CMV	Cytomegalovirus	299
CRP	C-reactive protein	300
CT	Computed tomography	301
EULAR	European Alliance of Associations for Rheumatology	302 303
ESR	Erythrocyte sedimentation rate	304
HBV	Hepatitis B virus	305
HCV	Hepatitis C virus	306
HIV	Human immunodeficiency virus	307
KFD	Kikuchi–Fujimoto disease	308
LVEF	Left ventricular ejection fraction	309
NSAIDs	Nonsteroidal anti-inflammatory drugs	310
SLE	Systemic lupus erythematosus	311

Conflict of interest

The authors declare that they have no conflict of interest
regarding the publication of this case report.

Funding

This study received no financial support.

Consent for publication

Written informed consent was obtained from the patient for
the publication of this case, including clinical information and
accompanying images.

Ethical approval

Ethical approval was not required for this case report in accord-
ance with institutional policies; however, all applicable ethical
standards and guidelines for research involving human subjects
were fully adhered to.

Author contributions

All authors participated in the preparation of the manuscript
and approved the final version.

Author details

Jesus Miguel Figueroa Zaldívar¹, Marco Antonio Rodríguez
Sánchez¹, Lucero Valenzuela Carvajal¹, Luis David Beltrán
Ontiveros¹, Omar Enrique Morales Flores¹, Ramón Antonio
Ruelas Estrada¹, Airam Acilegna Lopez Mercado¹
1. Internal Medicine Residency Program, Centro de
Investigación y Docencia en Ciencias de la Salud, Universidad
Autónoma de Sinaloa, Hospital Civil de Culiacán, Culiacán,
Mexico

References

1. Mahajan VK, Sharma V, Sharma N, Rani R. Kikuchi-
Fujimoto disease: a comprehensive review. *World J Clin
Cases*. 2023;11(16):3664–79. [https://doi.org/10.12998/
wjcc.v11.i16.3664](https://doi.org/10.12998/wjcc.v11.i16.3664)
2. Wright WF, Stelmash L, Betraíns A, Mulders-Manders CM,
Rovers CP, Vanderschueren S, et al. Recommendations
for updating fever and inflammation of unknown origin
from a modified Delphi consensus panel. *Open Forum
Infect Dis*. 2024;11(7):298. [https://doi.org/10.1093/ofid/
ofae298](https://doi.org/10.1093/ofid/ofae298)
3. Ray A, Muse VV, Boyer DF. A 30-year-old man with fever
and lymphadenopathy. *Case Records Massachusetts Gen
Hosp Case 38-2013 N Engl J Med*. 2013;369(24):2333–43.
<https://doi.org/10.1056/NEJMcp1310002>
4. Nishimura MF, Sakao C, Kurokawa Y, Nishimura Y,
Nishikori A, Yamamoto H, et al. Kikuchi-Fujimoto dis-
ease: investigating comprehensive clinicopathological

- 356 features and risk factors for recurrence. *Histopathology*. 370
 357 2025;87(1):68–80. <https://doi.org/10.1111/his.15427> 371
- 358 5. Hutchinson CB, Wang E. Kikuchi-Fujimoto disease. *Arch* 372
 359 *Pathol Lab Med*. 2010;134(2):289–93. [https://doi.](https://doi.org/10.5858/134.2.289) 373
 360 [org/10.5858/134.2.289](https://doi.org/10.5858/134.2.289) 374
- 361 6. Cellura AP. Kikuchi-Fujimoto disease in an adoles- 375
 362 cent boy. *Cutis Cutis*. 2021;108(3):E18–21. [https://doi.](https://doi.org/10.12788/cutis.0369) 376
 363 [org/10.12788/cutis.0369](https://doi.org/10.12788/cutis.0369) 377
- 364 7. Hutchinson CB, Wang E. Kikuchi-Fujimoto disease. *Arch* 378
 365 *Pathol Lab Med*. 2010;134(2):289–93. [https://doi.](https://doi.org/10.5858/134.2.289) 379
 366 [org/10.5858/134.2.289](https://doi.org/10.5858/134.2.289) 380
- 367 8. Yasukawa K, Matsumura T, Sato-Matsumura KC, 381
 368 Takahashi T, Fujioka Y, Kobayashi H, et al. Kikuchi’s 382
 369 disease and the skin: case report and review of the 383
- literature. *Br J Dermatol*. 2001;144(4):885–9. [https://doi.](https://doi.org/10.1046/j.1365-2133.2001.04151.x) 370
[org/10.1046/j.1365-2133.2001.04151.x](https://doi.org/10.1046/j.1365-2133.2001.04151.x) 371
9. Jiménez Sáenz JM, Llorente Arenas EM, Fuentes Solsona 372
 F, de Miguel García F, Álvarez Alegret R. Enfermedad de 373
 Kikuchi-Fujimoto y su asociación a lupus eritematoso sis- 374
 témico. *Med Interna (Madrid)*. 2001;18(8):39–41. [https://](https://doi.org/10.4321/S0212-71992001000800007) 375
doi.org/10.4321/S0212-71992001000800007 376
10. Serra-García L, Barba PJ, Morgado-Carrasco D. FR-Criterios 377
 de clasificación 2019 del lupus eritematoso sistémico. 378
Actas Dermosifiliogr. 2022;113(3):310–2. [https://doi.](https://doi.org/10.1016/j.ad.2020.04.021) 379
[org/10.1016/j.ad.2020.04.021](https://doi.org/10.1016/j.ad.2020.04.021) 380
11. Feder HM Jr, Liu J, Rezuke WN. Kikuchi disease in 381
 Connecticut. *J Pediatr*. 2014;164(1):196–200.e1. [https://](https://doi.org/10.1016/j.jpeds.2013.08.041) 382
doi.org/10.1016/j.jpeds.2013.08.041 383

Summary of the case

Item	Details
Age/sex	18-year-old male
Presentation	One-month history of persistent fever, malaise, asthenia, myalgias, arthralgias, non-pruritic rash, painful generalized lymphadenopathy (predominantly cervical), pharyngitis, weight loss, and night sweats
Key findings	Pancytopenia (Hb 8 g/dl, leukocytes 1,500/mm ³ with neutropenia, platelets 115,000/mm ³); elevated inflammatory markers (ESR 58 mm/h, CRP 384 mg/l, ferritin 753 ng/ml); CT scan showing generalized lymphadenopathy and hepatosplenomegaly; ANA 1:1,280 (homogeneous pattern); elevated anti-dsDNA antibodies
Diagnostic workup	Extensive infectious and hematologic evaluation negative; excisional inguinal lymph node biopsy showing necrotizing histiocytic lymphadenitis without neutrophils or malignancy, consistent with KFD
Diagnosis	KFD associated with SLE (EULAR/ACR 2019 score: 20 points)
Management	High-dose corticosteroids (prednisone 100 mg/day), hydroxychloroquine 200 mg/day, and azathioprine 50 mg/day
Outcome	Rapid clinical improvement with resolution of fever and symptoms; progressive normalization of hematologic parameters; discharged with outpatient rheumatology follow-up